Related Experiment Video
Updated: Sep 28, 2025
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.3K
Evolving Landscape of Systemic Therapy for Pediatric Atopic Dermatitis
Mary Kate Lockhart1, Elaine C Siegfried1
1Division of Dermatology, Department of Pediatrics, Cardinal Glennon Children's Hospital, St. Louis University School of Medicine, 1465 South Grand Boulevard, St. Louis, MO 63104, USA.
Dermatologic Clinics
|April 3, 2022
Summary
Systemic therapies, including dupilumab, offer safe and effective options for moderate-to-severe atopic dermatitis (AD) in children. Emerging treatments are also being investigated for pediatric AD management.
Area of Science:
- Dermatology
- Pediatrics
- Immunology
Background:
- Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition in children.
- Current standard treatments primarily involve topical therapies, with oral corticosteroids often used off-label for flares.
- The approval of dupilumab for adults marked a significant advancement, addressing an unmet need in moderate-to-severe AD.
Purpose of the Study:
- To review the safe and effective use of systemic therapies for moderate-to-severe atopic dermatitis in pediatric patients.
- To highlight the role of dupilumab in treating pediatric AD.
- To discuss promising emerging systemic treatments for pediatric AD.
Main Methods:
- Literature review of systemic therapies for moderate-to-severe atopic dermatitis in pediatric populations.
- Analysis of clinical data and guidelines regarding dupilumab and other systemic agents.
- Examination of emerging treatment modalities in pediatric AD.
Main Results:
- Topical therapies remain the standard of care for pediatric atopic dermatitis.
- Oral corticosteroids are frequently used for flares but are not recommended by guidelines.
- Dupilumab has demonstrated efficacy and safety in pediatric patients with moderate-to-severe AD.
- Several novel systemic treatments are under investigation for pediatric AD.
Conclusions:
- Systemic therapies, particularly dupilumab, represent a valuable addition to the treatment landscape for moderate-to-severe pediatric atopic dermatitis.
- Careful consideration of safety and efficacy is crucial when using systemic agents in children.
- Ongoing research into new systemic treatments holds promise for improved management of pediatric AD.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
772
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
772
01:14Changes in Skin Color: Clinical Perspectives
2.5K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
2.5K
01:30Asthma-IV: Diagnostic and Management
2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
613
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
613
01:26Asthma-II: Pathophysiology and Classification
3.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.0K
01:19Antiasthma Drugs: Leukotriene Modifiers
623
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
623